Journal of Cardiothoracic and Vascular Anesthesia 1997-02-01

Effects of lidoflazine on left ventricular function in patients.

S G De Hert, I E Rodrigus, L R Haenen, P W Ten Broecke, C J Boeckxstaens, T C Gillebert

Index: J. Cardiothorac. Vasc. Anesth. 11(1) , 42-8, (1997)

Full Text: HTML

Abstract

The present study evaluated the effects of the nucleoside transport inhibitor, lidoflazine, at a dose of 1 mg/kg, on left ventricular function.Patients were randomly assigned to receive either lidoflazine or saline in a double-blind manner.A university hospital.The study was performed in 32 patients scheduled for elective coronary artery bypass surgery.Left ventricular pressures were measured with fluid-filled catheters. Data were digitally recorded during pressure elevation induced by tilt-up of the legs. Transgastric short-axis echocardiographic views of the left ventricle were simultaneously recorded on videotape. Systolic function was evaluated with the slope (Ees, mmHg/mL) of the systolic pressure-volume relationship. Diastolic function was evaluated with the chamber stiffness constant (Kc, mmHg/mL) of the diastolic pressure-volume relationship. Cardiac function was assessed at baseline and after administration of either lidoflazine (group A [n = 16]) or placebo (group B [n = 16]). Data were compared using two-factor analysis of variance.At baseline, diastolic and systolic function were comparable in both groups. Lidoflazine increased Kc from 0.079 +/- 0.015 to 0.125 +/- 0.017 mmHg/mL and decreased Ees from 2.481 +/- 0.213 to 1.217 +/- 0.211 mmHg/mL (p = 0.009 and p = 0.004, respectively). None of these changes occurred when placebo was administered.Administration of lidoflazine before the start of cardiopulmonary bypass impaired left ventricular systolic function but also increased diastolic stiffness.


Related Compounds

Related Articles:

Protective effects of the lazaroid U74500A and lidoflazine on liver preservation with UW solution.

1993-01-01

[Transpl. Int. 6(5) , 281-4, (1993)]

Simpson's paradox and clinical trials: what you find is not necessarily what you prove.

1992-12-01

[Ann. Emerg. Med. 21(12) , 1480-2, (1992)]

1,4-Dihydropyridines bearing a pharmacophoric fragment of lidoflazine.

1996-10-01

[Bioorg. Med. Chem. 4(10) , 1629-35, (1996)]

The pathophysiology of angina pectoris and the effect of lidoflazine.

1982-01-01

[Circulation 65(1 Pt 2) , I27-32, (1982)]

Lidoflazine and myocardial protection.

1995-05-01

[J. Thorac. Cardiovasc. Surg. 109(5) , 1013-4; discussion 1015, (1995)]

More Articles...